Fukui R, Watanabe T, Morimoto K, Fujimoto Y, et al. An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers. Breast Cancer 2023;30:703-713.
PMID: 37115435